TARO Taro Pharmaceutical Industries Dashboard

Taro Pharmaceutical Industries Ltd. is engaged in the development, manufacturing, and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada, and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.

Company profile

Ticker

TARO

Exchange

NYSE

Website

www.taro.com

CEO

Uday Baldota

Location

Israel

Fiscal year end

Mar 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

SEC CIK

0000906338

Corporate docs

Articles of Incorporation & Bylaws

TARO stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

HC Wainwright & Co. Maintains Buy on Taro Pharmaceutical Indus, Raises Price Target to $81

1 Feb 21

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Taro Pharmaceutical Indus (NYSE:TARO) with a Buy and raises the price target from $80 to $81.

Taro Pharmaceutical Indus Q3 EPS $0.86 Misses $1.01 Estimate, Sales $140.10M Miss $152.63M Estimate

27 Jan 21

Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.86 per share which missed the analyst consensus estimate of $1.01 by 14.85 percent. This is a 51.14 percent decrease over earnings of $1.76 per

The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement

27 Jan 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26)

Earnings Scheduled For January 27, 2021

27 Jan 21

The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More

23 Jan 21

Press releases

Pro users get this 30m faster

Taro Provides Results for December 31, 2020

27 Jan 21

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and nine months ended December 31, 2020. Quarter ended December 31, 2020 Highlights ─

Taro to Announce Third Quarter Results on January 27, 2021

20 Jan 21

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2020, after the close of market on Wednesday, January 27,

Calendar

19 Jun 20

13 Apr 21

31 Mar 22

Financial summary

Financial statements Chart TARO financial data

Quarter (USD)	Mar 12
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 20	Mar 19	Mar 18	Mar 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership Q4 2020

TARO institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	83	76	+9.2%
Opened positions	17	5	+240.0%
Closed positions	10	11	-9.1%
Increased positions	26	28	-7.1%
Reduced positions	22	24	-8.3%

13F shares	Current	Prev Q	Change
Total value	369.03M	254.82M	+44.8%
Total shares	5.03M	4.66M	+8.1%
Total puts	0	10K	EXIT
Total calls	0	0
Total put/call ratio	–	Infinity	–

Largest owners	Shares	Value	Change
Renaissance Technologies	785.1K	$57.64M	+2.1%
FMR	678.74K	$49.83M	+1.3%
Krensavage Asset Management	553.65K	$40.65M	+3.0%
Dimensional Fund Advisors	478.99K	$35.17M	+1.0%
Brandes Investment Partners	412.21K	$29.8M	+20.6%
Acadian Asset Management	368.52K	$27.06M	-1.4%
NTRS Northern Trust	198.54K	$14.58M	+3.7%
Eversept Partners	152.26K	$11.18M	+7.3%
IVZ Invesco	152.24K	$11.18M	-9.7%
BLK Blackrock	150.77K	$11.07M	+10399.5%

Largest transactions	Shares	Bought/sold	Change
BLK Blackrock	150.77K	+149.34K	+10399.5%
Norges Bank	118.75K	+118.75K	NEW
APG Asset Management	0	-76.21K	EXIT
Brandes Investment Partners	412.21K	+70.44K	+20.6%
AMP Ameriprise Financial	82.17K	+68.71K	+510.7%
UBS UBS Group AG - Registered Shares	5.78K	-62.39K	-91.5%
Point72 Asset Management	42K	+42K	NEW
STT State Street	37.77K	+30.54K	+422.6%
Citadel Advisors	22.38K	-27.52K	-55.2%
Arrowstreet Capital, Limited Partnership	0	-23.61K	EXIT

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Akorn • Teligent

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: absorbed, academia, Academy, AFS, Aid, Alpha, amenable, Anatomic, Archemix, Australia, Baruch, behavior, Beta, Biocapital, Biology, biotech, border, Bridgewater, carryback, centralized, centralizing, Chase, Chemtech, claimant, Clocortolone, closure, cloud, communicable, constant, corruption, Daphne, defeated, defense, Dipropionate, distancing, doctorate, Dohme, Duke, DuPont, embedded, encryption, endpoint, Erik, EVP, Excellence, farm, FleetBoston, Fulbright, GE, Geron, Harvard, home, Honor, honorary, HSBC, Huang, Humanwell, IIC, IMA, Incyte, Indiana, Indore, inhibit, Inline, inquiry, Interactive, interchangeable, Internship, intervention, IRP, Kappa, Kinemed, landscape, learning, Leonard, Lifetime, Ligand, lung, magnitude, Melbourne, memorialized, Merit, mobile, Monash, monoclonal, Morgan, movement, MRR, Mupirocin, NaN, Ohio, Omega, Oncology, opioid, outbreak, outflow, Palo, pandemic, Pathology, perception, persist, Phi, Physiology, Pivalate, PRIORTECH, Protagenic, Puracap, rationalization, Relief, remittance, resolve, Robert, Roche, Roivant, RRSP, Samsara, Scholar, Scholarship, session, seventeen, Sharpe, Sigma, sixteen, slower, Society, specialist, speed, spread, spreading, Stein, stop, strain, Supreme, Syntex, tank, tied, unaudited, unconstitutional, undertook, unemployment, Unprecedented, vastly, widespread, XBRL, Xi, Zwicker

Removed: Adapalene, Agur, Aluminum, amalgamation, announcing, Argentina, Balaguer, Ballantine, Biopharma, carbamazepine, cetirizine, Clobetasol, Clomipramine, clorazepate, closing, comparability, Covington, Crescita, Cuyo, de, Desonide, Dewey, dichlorphenamide, dipotassium, Econazole, effecting, Elhanan, Elli, Esq, etodolac, extinguishment, fluocinonide, France, Henry, hereditary, hyperkalemic, hypokalemic, imposition, influencing, introductory, Italy, ITGI, Kennedy, lamotrigine, mandate, Manzano, Mariano, muscle, Nacional, naftifine, NCR, nitrate, Notably, Nutrition, orphan, oxiconazole, predominance, prepayment, Propionate, rare, Retalix, rolling, Schein, securitization, Shigamab, slightly, Stephen, Streit, Strongbridge, terbinafine, Thallion, threat, TP, Universidad, upfront, veterinary, VP, warfarin, Weizmann, Wharton, Yeda

From filing 20-F 2020 FY